Skip to main content
SpringerLink
Log in

Evaluation of 2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl) hexanamide (NPC 15437), a protein kinase C inhibitor, as a modulator of P-glycoprotein-mediated resistancein vitro

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

We assessed the effect of the protein kinase C inhibitor 2,6-diamino-N-([1-(1-oxotridecyl)-2-piperidinyl] methyl)hexanamide (NPC 15437) on the action of anthracyclines, epipodophyllotoxins and vinca alkaloids in P-glycoprotein (Pgp)-expressing CHRC5 hamster ovary and MCF-7/AdriaR human breast cancer cells. Flow microfluorimetry revealed that treatment of CHRC5 cells with 75 μM NPC 15437 for 1 h resulted in a 6- to 10-fold increase in the nuclear accumulation of daunorubicin. Colony forming assays revealed that treatment with 75 μM NPC 15437 was associated with a 4-fold decrease in the LD90 for etoposide and a 2.5-fold decrease in the LD50 for vincristine. At higher concentrations of NPC 15437, greater modulation of anthracycline accumulation was observed; but NPC 15437 itself inhibited subsequent colony formation. Similar effects on drug accumulation and cytotoxicity were observed in MCF-7/AdriaR cells. Experiments designed to investigate the mechanism by which NPC 15437 exerts these effects revealed that treatment with the protein kinase C activator phorbol-12-myristate 12-acetate partially reversed the effect of NPC 15437, suggesting that NPC 15437 was exerting an effect through protein kinase C. Photoaffinity labeling experiments revealed that NPC 15437 also inhibited the binding of [3H]-azidopine to Pgp in isolated membrane vesicles. These results identify NPC 15437 as the prototype of a new class of potential Pgp modulators but indicate that the effects of this agent as a modulator are potentially limited by its cytotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beck WT: The cell biology of multiple drug resistance. Biochem Pharmacol 36:2879, 1987

    Article  PubMed  Google Scholar 

  2. Gottesman MM, Pastan I: The multidrug transporter, a double-edged sword. J Biol Chem 263:12163, 1988

    PubMed  Google Scholar 

  3. Endicott JA, Ling V: The biochemistry of P-glycoprotein mediated multidrug resistance. Annual Rev Biochem 58:137, 1989

    Google Scholar 

  4. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharm Rev 42:155, 1990

    PubMed  Google Scholar 

  5. Cordon-Cardo C, O'Brien JP: The multidrug resistance phenotype in human cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Important Advances in Oncology. JB Lippincott, Philadelphia, 1991, pp 19–38

    Google Scholar 

  6. Fine RL, Patel J, Chabner BA: Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 85:582, 1988

    PubMed  Google Scholar 

  7. O'Brian CA, Fan D, Ward NE, Seid C, Fidler U: Level of protein kinase C activity correlates directly with resistance to adriamycin in murine fibrosarcoma cells. FEBS Letters 246:78, 1989

    PubMed  Google Scholar 

  8. Posada J, Vichi P, Tritton TR: Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells. Cancer Res 49:6634, 1989

    PubMed  Google Scholar 

  9. Posada JA, McKeegan EM, Worthington KF, Morin MJ, Jaken S, Tritton TR: Human multidrug resistant KB cells overexpress protein kinase C: Involvement in drug resistance. Cancer Commun 1:285, 1989

    PubMed  Google Scholar 

  10. Chambers TC, Chalikonda I, Eilon G: Correlation of protein kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells. Biochem Biophys Res Commun 169:253, 1990

    PubMed  Google Scholar 

  11. Ward NE, O'Brian CA: Distinct patterns of phorbol ester-induced downregulation of protein kinase C activity in adriamycin-selected multidrug resistant and parental murine fibrosarcoma cells. Cancer Letters 58:189, 1991

    PubMed  Google Scholar 

  12. Gollapudi S, Patel K, Jain V, Gupta S: Protein kinase C isoforms in multidrug resistant P388/ADR cells: A possible role in daunorubicin transport. Cancer Letters 62:69, 1992

    PubMed  Google Scholar 

  13. Dolci ED, Abramson R, Xuan Y, Siegfried J, Yuenger KA, Yassa DS, Tritton TR: Anomalous expression of P-glycoprotein in highly drug-resistant human KB cells. Int J Cancer 54:302, 1993

    PubMed  Google Scholar 

  14. Chambers TC, McAvoy EM, Jacobs JW, Elion G: Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem 265:7679, 1990

    PubMed  Google Scholar 

  15. Chambers TC, Zheng B, Kuo JF: Regulation by phorbol ester and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells. Mol Pharmacol 41:1008, 1992

    PubMed  Google Scholar 

  16. Ferguson PJ, Cheng Y-C: Transient protection of cultured human cells against antitumor agents by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 47:433, 1987

    PubMed  Google Scholar 

  17. Hamada H, Hagiwara K-I, Nakajima T, Tsuruo T: Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: Effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res 47:2860, 1987

    PubMed  Google Scholar 

  18. Dong Z, Ward NE, Fan D, Gupta KP, O'Brien CA:In vitro model for intrinsic drug resistance: Effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells. Mol Pharmacol 39:563, 1991

    PubMed  Google Scholar 

  19. Bates SE, Lee JS, Dickstein B, Spolyar M, Fojo AT: Differential modulation of P-glycoprotein transport by protein kinase inhibition. Biochemistry 32:9156, 1993

    PubMed  Google Scholar 

  20. Schwartz GK, Arkin H, Holland JF, Ohnuma T: Protein kinase C activity and multidrug resistance in MOLT-3 human lymphoblastic leukemia cells resistant to trimetrexate. Cancer Res 51:55, 1991

    PubMed  Google Scholar 

  21. Yu G, Ahmad S, Aquino A, Fairchild CR, Trepel JB, Ohno S, Suzuki K, Tsuruo T, Cowan KH, Glazer RI; Transfection with protein kinase Cα confers increased multidrug resistance to MCF-7 cells expressing Pglycoprotein. Cancer Comm 3:181, 1991

    PubMed  Google Scholar 

  22. Fan D, Fidler U, Ward NE, Seid C, Earnest LE, Housey GM, O'Brian CA: Stable expression of a cDNA encoding rat brain protein kinase C-βI confers a multidrug-resistant phenotype on rat fibroblasts. Anticancer Res 12:661, 1992

    PubMed  Google Scholar 

  23. Ahmad S, Safa AR, Glazer RI: Modulation of P-glycoprotein by protein kinase C alpha in baculovirus expression system. Biochem 33:10313, 1994

    PubMed  Google Scholar 

  24. Smith CD, Zilfou JT: Circumvention of P-glycoproteinmediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. J Biol Chem 270:28145, 1995

    Article  PubMed  Google Scholar 

  25. Ahmad S, Glazer RI: Expression of the antisense cDNA for protein kinase Ca attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol 42:858, 1993

    Google Scholar 

  26. Sato W, Yusa K, Naito M, Tsuruo T: Staurosporine, a potent inhibitor of C-Kinase, enhances drug accumulation in multidrug resistant cells. Biochem Biophys Res Commun 173:1252, 1990

    PubMed  Google Scholar 

  27. Wakusawa S, Nakamura S, Tajima K, Miyamoto K, Hagiwara M, Hidaka H: Overcoming of vinblastine resistance by isoquinolinesulfonamide compounds in adriamycin-resistant leukemia cells. Mol Pharmacol 41:1034, 1992

    PubMed  Google Scholar 

  28. Nakano H, Kobayashi E, Takahashi I, Tamaoki T, Kuquu Y, Iba H: Staurosporine inhibits tyrosine-specific protein kinase activity of rouse sarcoma virus transforming protein p60. J Antibiotics 40:706, 1986

    Google Scholar 

  29. Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita F: Staurosporine, a potent inhibitor of phospholipid/Ca++ dependent protein kinase. Biochem Biophys Res Commun 135:397, 1986

    PubMed  Google Scholar 

  30. Sullivan JP, Connor JR, Tiffany C, Shearer BG, Burch RM: NPC 15437 interacts with the Cl domain of protein kinase C. FEBS Letters 285:120, 1991

    PubMed  Google Scholar 

  31. Sullivan JP, Connor JR, Shearer BG, Burch RM: 2,6-Diamino-N-([1 -(1-oxotridecyl)-2-piperidinyl]methyl) hexanamide (NPC 15437): A novel inhibitor of protein kinase C interacting at the regulatory domain. Mol Pharmacol 41:38, 1992

    PubMed  Google Scholar 

  32. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52:2268, 1992

    PubMed  Google Scholar 

  33. Kaufmann SH: Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51:1129–1136, 1991

    PubMed  Google Scholar 

  34. Bech-Hansen NT, Till JE, Ling V: Pleiotropic phenotype of colchicine-resistant CHO cells: cross-resistance and collateral sensitivity. J Cell Phys 88(1):23–31, 1976

    PubMed  Google Scholar 

  35. Van der Bliek AM, Van der Velde-Koerts T, Ling V, Borst P: Overexpression and amplification of five genes in a multidrug-resistant Chinese hamster ovary cell line. Mol Cell Biol:1671–1678, 1986

  36. Fairchild CR, Ivy P, Kao-Shan C-S, Whang-Peng J, Rosen N, Israel MA, Melera PW, Cowan KH, Goldsmith ME: Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res 47:5141–5148, 1987

    PubMed  Google Scholar 

  37. Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL, Felsted RL: Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 262:7884, 1987

    PubMed  Google Scholar 

  38. Yang C-PH, DePinho SG, Greenberger LM, Arceci RJ, Horwitz SB: Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem 264:782, 1989

    PubMed  Google Scholar 

  39. Lever J: Active amino acid transport in plasma membrane vesicles from simian virus 40-transformed mouse fibroblasts. Characteristics of electrochemical Na+ gradient-stimulated uptake. J Biol Chem 252:1990, 1977

    PubMed  Google Scholar 

  40. Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochem 72:248, 1976

    Article  PubMed  Google Scholar 

  41. Greenberger LM, Williams SS, Georges E, Ling V, Horwitz SB: Electrophoretic analysis of P-glycoproteins produced by mouse J774.2 and Chinese hamster ovary multidrug-resistant cells. J Natl Cancer Institute 80:506, 1988

    Google Scholar 

  42. Pearce HL, Safa AR, Bach NJ, Winter MA, Cirtain MC, Beck WT: Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci USA 86:5128, 1989

    PubMed  Google Scholar 

  43. D'Incalci M: DNA-topoisomerase inhibitors. Current Opinion in Oncology 5(6);1023–1028, 1993

    PubMed  Google Scholar 

  44. Chen AY, Liu LF:DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34:191–218, 1994

    PubMed  Google Scholar 

  45. Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G, Kohn KW: Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Investigation 12(5):530–542, 1994

    PubMed  Google Scholar 

  46. Sahyoun NE, Wolf M, Besterman J, Hsieh T-S, Sander M, Le Vine H, Chang K-J, Cuatrecases P: Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. Proc Natl Acad Sci USA 83:1603–1607, 1986

    PubMed  Google Scholar 

  47. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258:607, 1992

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins Oncology Center and Department of Pharmacology, Johns Hopkins University School of Medicine, 21287, Baltimore, Maryland, USA

    Edward C. Sha, Michael C. Sha & Scott H. Kaufmann M.D., Ph.D.

Authors
  1. Edward C. Sha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael C. Sha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Scott H. Kaufmann M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sha, E.C., Sha, M.C. & Kaufmann, S.H. Evaluation of 2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl) hexanamide (NPC 15437), a protein kinase C inhibitor, as a modulator of P-glycoprotein-mediated resistancein vitro . Invest New Drugs 13, 285–294 (1995). https://doi.org/10.1007/BF00873134

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00873134

Key words

Search

Navigation